Navigation Links
Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain

SAN FRANCISCO, Feb. 25, 2013 /PRNewswire/ -- Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in a Phase 2 study of its lead investigational drug candidate for the prevention of post-surgical pain, AYX1.

The 90-patient, placebo-controlled study will evaluate the safety and efficacy of a single administration of AYX1 given prior to unilateral total knee arthroplasty (TKA) to reduce acute pain and to prevent the transition to persistent pain. The study will follow patients for 42 days, with a primary endpoint of pain with walking. Secondary and exploratory endpoints will include pain at rest, pain with knee range of motion, rate and extent of functional recovery, opioid consumption and safety assessments. Further details of the study can be found at

"While many widely used pain therapies require repeat dosing for symptom amelioration, or require heavy dosing with associated side-effects to treat pain with movement, a single administration of AYX1 has the potential to block the development of pain before it begins," said Donald Manning , M.D., Ph.D., chief medical officer of Adynxx. "This study will evaluate AYX1's ability to reduce acute pain and prevent persistent pain, especially pain associated with movement, enabling patients to begin rehabilitation and resume other activities earlier."

Dennis Podlesak , chairman of the Adynxx board of directors, added, "AYX1 is a novel new treatment option that has the potential to transform how patients suffering from post-surgical pain are treated, and to provide patients and physicians with an innovative and advantageous approach to pain management.  The clinical and preclinical results to date are certainly promising, and we look forward to evaluating the efficacy of this potentially breakthrough therapy for the first time in patients.  The overall development plan laid out by the Adynxx team positions AYX1 well to meet the needs of millions of patients who suffer from pain after surgery every year."

Funded exclusively by Domain Associates, Adynxx completed a Phase 1 safety study in healthy volunteers in September 2012 and progressed rapidly to the initiation of its Phase 2 clinical study. 

About Adynxx

Adynxx, Inc. is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots, which potentially prevents the development of pain following surgery or trauma and resolves established chronic pain syndromes. Adynxx's unique approach is to transform pain management by addressing pain as a disease rather than a symptom.

Adynxx's lead compound, AYX1, is an investigational drug designed to reduce acute post-surgical pain and prevent the transition to persistent or chronic pain with a single administration at the time of surgery. A Phase 2 study evaluating a single dose of AYX1 prior to unilateral total knee arthroplasty is ongoing. Additional therapeutic candidates in the AYX platform which are intended to resolve multiple forms of chronic lower back pain, intractable neuropathic and inflammatory pain syndromes are currently under active preclinical development.

Media Contact:

David Schull or Ian Stone
Russo Partners
(858) 717-2310
(619) 308-6541


Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study
2. Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1
3. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
4. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
5. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
6. The Emirate of Abu Dhabi Becomes First to Have JCI Accredited Long-Term Care Facility Outside of USA
7. Specialty Pharmacy Association of America (SPAARx) - Enrollment Exceeds 1,000 Members in First Two Weeks since Launch
8. Research Units Across the World go for the First 3 Tesla, Cryogen Free MRI Bench Top Scanner
9. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
10. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
11. Smt. Sheila Dikshit Unveils South Asias First PET SUITE at Indraprastha Apollo Hospitals
Post Your Comments:
(Date:11/24/2015)... -- iRhythm Technologies, Inc. , a leading digital health care ... will participate in the 27th Annual Piper Jaffray Healthcare Conference at ... . Kevin King , Chief Executive Officer of ... 8:50am ET. --> --> ... . --> iRhythm is a privately held ...
(Date:11/24/2015)... Mass. , Nov. 24, 2015  Boston Scientific ... in the Oppenheimer 26th Annual Healthcare Conference on December ... Susie Lisa , vice president, Investor Relations, ... host analyst beginning at approximately 8:35 a.m. ET. ... will participate in a 30-minute question-and-answer session with the ...
(Date:11/24/2015)... , Nov. 24, 2015  BioPlast Manufacturing, ... the medical research, clinical diagnostic and biotech environments, ... leading manufacturer of quality petri dishes. This acquisition ... clients a platform of products that are designed ... with the highest quality.  ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... The American ... support their local poison centers through donations on Tuesday, Dec. 1, 2015. Since ... “a day that inspires people to collaborate in improving their local communities and ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... With Thanksgiving ... Insurance is sharing safety tips to help protect your family and vehicle. , According ... around the 2013 Thanksgiving holiday weekend. Amica is sharing the following safety tips from ...
(Date:11/24/2015)... ... November 24, 2015 , ... Abington Hospital ... Aetna Institute of Quality® Bariatric Surgery Facility for treating individuals living with morbid ... health care services available to its members to help them make informed decisions ...
(Date:11/24/2015)... ... 2015 , ... Sir Grout of Baltimore is proud to ... award recognizes good companies for excellence in service and a commitment to the ... surface restoration company earned this recognition after a thorough review by the acclaimed ...
(Date:11/24/2015)... N.Y. (PRWEB) , ... November 24, 2015 , ... Autism ... Tuesday, the global movement driven by social media and the generosity of people around ... then encourage their social media networks to give – and share the personal stories ...
Breaking Medicine News(10 mins):